XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Cash Flows from Operating Activities    
Net income $ 4,767 $ 2,825
Adjustments to reconcile net income to net cash provided by operating activities:    
Amortization 473 543
Depreciation 511 448
Income from investments in equity securities, net (143) (450)
Charge for the acquisition of Harpoon Therapeutics, Inc. 656 0
Charge for the acquisition of Imago BioSciences, Inc. 0 1,192
Deferred income taxes (51) (277)
Share-based compensation 176 145
Other 83 (197)
Net changes in assets and liabilities (3,382) (2,890)
Net Cash Provided by Operating Activities 3,090 1,339
Cash Flows from Investing Activities    
Capital expenditures (861) (1,007)
Purchases of securities and other investments (15) (562)
Proceeds from sales of securities and other investments 260 500
Acquisition of Harpoon Therapeutics, Inc., net of cash acquired (746) 0
Acquisition of Imago BioSciences, Inc., net of cash acquired 0 (1,327)
Other (14) 37
Net Cash Used in Investing Activities (1,376) (2,359)
Cash Flows from Financing Activities    
Payments on debt (751) (1)
Dividends paid to stockholders (1,950) (1,853)
Purchases of treasury stock (122) (149)
Proceeds from exercise of stock options 87 30
Other (78) (81)
Net Cash Used in Financing Activities (2,814) (2,054)
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash (138) 87
Net Decrease in Cash, Cash Equivalents and Restricted Cash (1,238) (2,987)
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $68 and $79 at January 1, 2024 and 2023, respectively, included in Other current assets) 6,909 12,773
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $92 and $79 at March 31, 2024 and 2023, respectively, included in Other current assets) $ 5,671 $ 9,786